desvenlafaxine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4380	93413-62-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: desvenlafaxine desvenlafaxine succinate pristiq DVS-233 desvenlafaxine fumarate	The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). Molecular weight: 263.38 Formula: C16H25NO2 CLOGP: 2.68 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 43.70 ALOGS: -2.27 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

desvenlafaxine
desvenlafaxine succinate
pristiq
DVS-233
desvenlafaxine fumarate

The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).

Molecular weight: 263.38
Formula: C16H25NO2
CLOGP: 2.68
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 43.70
ALOGS: -2.27
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	572 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	45 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.42 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	3.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.70 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 29, 2008	FDA	WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product residue present	752.66	15.15	197	21967	3475	50579485
Drug withdrawal syndrome	632.85	15.15	278	21886	24803	50558157
Suicidal ideation	342.30	15.15	243	21921	55142	50527818
Withdrawal syndrome	288.70	15.15	145	22019	17445	50565515
Feeling abnormal	275.77	15.15	306	21858	125186	50457774
Crying	268.33	15.15	145	22019	20271	50562689
Anxiety	231.97	15.15	334	21830	177272	50405688
Insomnia	218.39	15.15	322	21842	174543	50408417
Irritability	197.18	15.15	134	22030	28292	50554668
Dizziness	167.27	15.15	426	21738	345943	50237017
Anger	133.73	15.15	75	22089	11258	50571702
Nausea	130.22	15.15	630	21534	704768	49878192
Hyperhidrosis	113.26	15.15	166	21998	89260	50493700
Headache	109.94	15.15	475	21689	506060	50076900
Condition aggravated	98.92	15.15	320	21844	296738	50286222
Panic attack	94.95	15.15	74	22090	19268	50563692
Nervousness	92.86	15.15	85	22079	27566	50555394
Agitation	90.17	15.15	114	22050	53270	50529690
Depression	88.51	15.15	212	21952	165211	50417749
Tremor	87.59	15.15	170	21994	114733	50468227
Emotional disorder	87.31	15.15	58	22106	11778	50571182
Abnormal dreams	84.16	15.15	52	22112	9325	50573635
Intentional product misuse	84.05	15.15	103	22061	46631	50536329
Feeling jittery	73.54	15.15	51	22113	11109	50571851
Suicide attempt	63.95	15.15	95	22069	51637	50531323
Nightmare	63.07	15.15	54	22110	16032	50566928
Completed suicide	62.04	15.15	161	22003	131728	50451232
Thinking abnormal	61.35	15.15	43	22121	9524	50573436
Persistent genital arousal disorder	58.80	15.15	15	22149	237	50582723
Serotonin syndrome	51.93	15.15	59	22105	24654	50558306
Disturbance in attention	50.12	15.15	65	22099	31121	50551839
Overdose	49.21	15.15	124	22040	99603	50483357
Middle insomnia	48.77	15.15	38	22126	9883	50573077
Migraine	47.41	15.15	103	22061	75177	50507783
Paraesthesia	46.80	15.15	137	22027	120106	50462854
Seizure	43.69	15.15	132	22032	117742	50465218
Drug ineffective	43.68	15.15	548	21616	818785	49764175
Depressed mood	42.78	15.15	63	22101	33960	50549000
Vision blurred	42.20	15.15	101	22063	78546	50504414
Acute kidney injury	41.79	15.15	24	22140	228034	50354926
Anaemia	41.58	15.15	30	22134	252426	50330534
Pyrexia	41.56	15.15	64	22100	380139	50202821
Mania	41.48	15.15	36	22128	10880	50572080
Drug screen positive	41.45	15.15	23	22141	3379	50579581
Tinnitus	41.15	15.15	56	22108	28076	50554884
Mydriasis	40.29	15.15	35	22129	10592	50572368
Synovitis	39.88	15.15	4	22160	123861	50459099
Anorgasmia	38.98	15.15	13	22151	542	50582418
Death	38.27	15.15	52	22112	325327	50257633
Energy increased	38.20	15.15	19	22145	2233	50580727
Impaired driving ability	38.19	15.15	23	22141	3938	50579022
Product substitution issue	37.34	15.15	38	22126	14019	50568941
Coma scale abnormal	36.69	15.15	24	22140	4747	50578213
Neutropenia	36.19	15.15	10	22154	147955	50435005
Joint swelling	35.61	15.15	33	22131	245253	50337707
Somnolence	35.39	15.15	148	22016	154837	50428123
Maternal exposure during pregnancy	35.17	15.15	13	22151	159765	50423195
Blood pressure increased	35.11	15.15	133	22031	132999	50449961
Mood altered	34.79	15.15	35	22129	12738	50570222
Treatment failure	34.23	15.15	9	22155	137628	50445332
Drug screen false positive	34.04	15.15	13	22151	806	50582154
Aggression	33.90	15.15	44	22120	21072	50561888
Systemic lupus erythematosus	33.47	15.15	10	22154	140612	50442348
Pre-existing condition improved	32.34	15.15	26	22138	7071	50575889
Therapeutic response unexpected	31.75	15.15	37	22127	15878	50567082
Weight increased	31.70	15.15	173	21991	201718	50381242
Stomatitis	30.80	15.15	4	22160	101340	50481620
Restlessness	30.76	15.15	46	22118	25127	50557833
Peripheral swelling	30.72	15.15	27	22137	205909	50377051
Thrombocytopenia	30.53	15.15	9	22155	127664	50455296
Drug hypersensitivity	30.41	15.15	201	21963	250809	50332151
Bruxism	30.21	15.15	18	22146	3022	50579938
Infusion related reaction	29.43	15.15	19	22145	169538	50413422
Paranoia	29.37	15.15	29	22135	10319	50572641
General physical health deterioration	29.05	15.15	13	22151	142421	50440539
Mood swings	28.40	15.15	35	22129	15919	50567041
Palpitations	27.93	15.15	98	22066	94408	50488552
Nonspecific reaction	27.22	15.15	14	22150	1765	50581195
Rheumatoid arthritis	26.27	15.15	30	22134	202520	50380440
Libido decreased	26.07	15.15	15	22149	2361	50580599
Sepsis	25.77	15.15	13	22151	132912	50450048
Amnesia	25.66	15.15	57	22107	42203	50540757
Tachyphrenia	25.65	15.15	12	22152	1233	50581727
Abnormal behaviour	25.58	15.15	37	22127	19621	50563339
Euphoric mood	25.47	15.15	18	22146	4037	50578923
Mental disorder	25.19	15.15	39	22125	21952	50561008
Hostility	24.35	15.15	13	22151	1769	50581191
Infection	24.23	15.15	24	22140	172930	50410030
Pericarditis	24.16	15.15	3	22161	78686	50504274
Lower respiratory tract infection	24.09	15.15	6	22158	95195	50487765
Dissociation	23.91	15.15	14	22150	2277	50580683
Hypersensitivity vasculitis	23.33	15.15	17	22147	3998	50578962
Panic reaction	22.78	15.15	16	22148	3553	50579407
Loss of libido	22.78	15.15	11	22153	1212	50581748
Stress	22.56	15.15	63	22101	53730	50529230
Unevaluable event	22.40	15.15	57	22107	46009	50536951
Post-traumatic stress disorder	22.28	15.15	17	22147	4286	50578674
Prescribed overdose	21.25	15.15	29	22135	14571	50568389
Bipolar disorder	21.18	15.15	20	22144	6737	50576223
Apathy	21.14	15.15	21	22143	7527	50575433
Pneumonia	20.30	15.15	91	22073	378310	50204650
Muscle twitching	20.01	15.15	29	22135	15402	50567558
Hallucination	19.92	15.15	55	22109	46602	50536358
Negative thoughts	19.88	15.15	9	22155	857	50582103
Swelling	19.87	15.15	36	22128	200836	50382124
Arthropathy	19.81	15.15	24	22140	157882	50425078
Febrile neutropenia	19.77	15.15	9	22155	97658	50485302
Brain injury	19.23	15.15	18	22146	5996	50576964
Dyspnoea	19.15	15.15	151	22013	547457	50035503
Suicidal behaviour	18.58	15.15	12	22152	2322	50580638
Wrong technique in product usage process	18.54	15.15	60	22104	55450	50527510
Memory impairment	18.25	15.15	76	22088	79284	50503676
Tardive dyskinesia	18.11	15.15	19	22145	7260	50575700
Tearfulness	17.86	15.15	14	22150	3673	50579287
Intestinal pseudo-obstruction	17.83	15.15	8	22156	746	50582214
Change in seizure presentation	17.55	15.15	6	22158	270	50582690
Malaise	17.51	15.15	224	21940	335308	50247652
Haemoglobin decreased	17.41	15.15	18	22146	127198	50455762
Renal impairment	16.90	15.15	6	22158	75655	50507305
Hallucination, auditory	16.67	15.15	22	22142	10706	50572254
Urinary tract infection	16.58	15.15	47	22117	223973	50358987
Dry mouth	16.37	15.15	58	22106	56120	50526840
Yawning	16.21	15.15	8	22156	925	50582035
Impatience	16.09	15.15	6	22158	348	50582612
Decreased interest	15.95	15.15	12	22152	2964	50579996
Feeling drunk	15.84	15.15	13	22151	3640	50579320
Blood triglycerides increased	15.76	15.15	22	22142	11290	50571670
Galactorrhoea	15.62	15.15	13	22151	3710	50579250
Wound	15.60	15.15	14	22150	105780	50477180
Coma	15.57	15.15	3	22161	56876	50526084
Wernicke-Korsakoff syndrome	15.46	15.15	4	22160	67	50582893
Impaired work ability	15.36	15.15	24	22140	13616	50569344
Drug effective for unapproved indication	15.19	15.15	10	22154	1999	50580961

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product residue present	225.41	22.80	60	6027	2479	29565961
Drug withdrawal syndrome	170.05	22.80	80	6007	17904	29550536
Serotonin syndrome	141.61	22.80	70	6017	17442	29550998
Suicidal ideation	118.41	22.80	79	6008	34637	29533803
Anxiety	90.28	22.80	99	5988	85266	29483174
Hyperhidrosis	73.70	22.80	78	6009	64462	29503978
Suicide attempt	65.43	22.80	55	6032	34055	29534385
Overdose	61.82	22.80	79	6008	79740	29488700
Sexual dysfunction	58.39	22.80	27	6060	5787	29562653
Withdrawal syndrome	52.48	22.80	31	6056	10961	29557479
Insomnia	50.89	22.80	76	6011	88685	29479755
Feeling abnormal	50.40	22.80	59	6028	54386	29514054
Anger	50.13	22.80	30	6057	10860	29557580
Major depression	45.47	22.80	20	6067	3815	29564625
Drug ineffective	45.19	22.80	170	5917	363000	29205440
Thinking abnormal	39.53	22.80	20	6067	5216	29563224
Completed suicide	39.02	22.80	68	6019	90178	29478262
Erectile dysfunction	36.50	22.80	30	6057	17979	29550461
Schizophreniform disorder	35.65	22.80	7	6080	70	29568370
Coma scale abnormal	34.49	22.80	16	6071	3453	29564987
Nervousness	34.37	22.80	24	6063	11282	29557158
Dry mouth	33.48	22.80	31	6056	21753	29546687
Depression	30.29	22.80	59	6028	85088	29483352
Mania	30.16	22.80	20	6067	8643	29559797
Headache	29.93	22.80	91	5996	173916	29394524
Libido decreased	28.36	22.80	15	6072	4283	29564157
Tremor	27.43	22.80	52	6035	73486	29494954
Drug screen positive	27.18	22.80	14	6073	3787	29564653
Abnormal behaviour	26.42	22.80	28	6059	23099	29545341
Irritability	25.63	22.80	27	6060	22125	29546315
Paralysis	24.92	22.80	15	6072	5482	29562958
Acute kidney injury	24.57	22.80	12	6075	265255	29303185
Drug screen false positive	24.51	22.80	8	6079	672	29567768
Dizziness	24.43	22.80	90	5997	189594	29378846
Paraesthesia	23.79	22.80	41	6046	53804	29514636
Emotional disorder	23.77	22.80	14	6073	4917	29563523
Intentional product misuse	23.21	22.80	32	6055	34629	29533811
Bipolar disorder	23.17	22.80	12	6075	3283	29565157

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Withdrawal syndrome	278.99	15.26	135	18060	23357	64457180
Drug withdrawal syndrome	234.30	15.26	132	18063	31159	64449378
Suicidal ideation	219.58	15.26	168	18027	66374	64414163
Feeling abnormal	208.52	15.26	221	17974	133381	64347156
Product residue present	183.69	15.26	58	18137	3184	64477353
Anxiety	175.58	15.26	249	17946	202400	64278137
Crying	164.72	15.26	90	18105	20000	64460537
Serotonin syndrome	140.19	15.26	104	18091	39178	64441359
Irritability	126.02	15.26	95	18100	36651	64443886
Overdose	115.00	15.26	180	18015	159386	64321151
Anger	103.36	15.26	61	18134	15680	64464857
Insomnia	100.31	15.26	191	18004	197645	64282892
Suicide attempt	99.32	15.26	111	18084	70896	64409641
Dizziness	86.56	15.26	292	17903	429871	64050666
Completed suicide	85.91	15.26	193	18002	224221	64256316
Hyperhidrosis	81.83	15.26	135	18060	124785	64355752
Emotional disorder	77.93	15.26	47	18148	12560	64467977
Depression	75.05	15.26	162	18033	183129	64297408
Coma scale abnormal	69.78	15.26	37	18158	7737	64472800
Headache	67.93	15.26	312	17883	529155	63951382
Persistent genital arousal disorder	65.78	15.26	15	18180	230	64480307
Drug ineffective	64.18	15.26	430	17765	839817	63640720
Nausea	62.31	15.26	406	17789	785394	63695143
Drug hypersensitivity	62.14	15.26	177	18018	237638	64242899
Tremor	61.78	15.26	132	18063	148098	64332439
Nervousness	59.06	15.26	56	18139	29500	64451037
Intentional product misuse	56.84	15.26	85	18110	72210	64408327
Panic attack	56.41	15.26	47	18148	20906	64459631
Acute kidney injury	55.23	15.26	29	18166	449211	64031326
Depressed mood	52.05	15.26	61	18134	40951	64439586
Thinking abnormal	51.37	15.26	35	18160	11521	64469016
Product substitution issue	47.94	15.26	40	18155	17821	64462716
Abnormal dreams	47.54	15.26	32	18163	10324	64470213
Nightmare	46.24	15.26	42	18153	20951	64459586
Major depression	40.37	15.26	26	18169	7790	64472747
Agitation	38.29	15.26	80	18115	88287	64392250
Migraine	36.07	15.26	64	18131	62613	64417924
Feeling jittery	35.34	15.26	27	18168	10608	64469929
Condition aggravated	33.42	15.26	199	17996	372227	64108310
Neutropenia	33.25	15.26	13	18182	239611	64240926
Impaired driving ability	33.09	15.26	19	18176	4635	64475902
Anaemia	32.91	15.26	35	18160	378645	64101892
Tinnitus	32.52	15.26	44	18151	34089	64446448
Mood altered	31.39	15.26	30	18165	15949	64464588
Mental disorder	31.35	15.26	38	18157	26407	64454130
Thrombocytopenia	31.28	15.26	12	18183	223789	64256748
Mania	30.90	15.26	30	18165	16256	64464281
Paranoia	30.80	15.26	30	18165	16322	64464215
Pre-existing condition improved	30.07	15.26	18	18177	4744	64475793
Febrile neutropenia	29.88	15.26	8	18187	187649	64292888
Seizure	29.69	15.26	109	18086	166783	64313754
Disturbance in attention	29.04	15.26	46	18149	41028	64439509
Prescribed overdose	28.77	15.26	32	18163	20299	64460238
Abnormal behaviour	28.53	15.26	41	18154	33581	64446956
General physical health deterioration	28.50	15.26	11	18184	204414	64276123
Schizophreniform disorder	28.40	15.26	7	18188	152	64480385
Sepsis	28.06	15.26	15	18180	230326	64250211
Panic reaction	27.46	15.26	16	18179	4011	64476526
Hostility	27.13	15.26	13	18182	2194	64478343
Pyrexia	26.35	15.26	76	18119	558568	63921969
Mood swings	25.59	15.26	28	18167	17440	64463097
Therapeutic response unexpected	24.47	15.26	27	18168	16974	64463563
Suicidal behaviour	23.83	15.26	13	18182	2874	64477663
Reversible cerebral vasoconstriction syndrome	23.46	15.26	12	18183	2330	64478207
Paraesthesia	22.37	15.26	86	18109	134436	64346101
Bipolar disorder	22.10	15.26	17	18178	6744	64473793
Hypersensitivity vasculitis	22.10	15.26	17	18178	6744	64473793
Affect lability	21.81	15.26	19	18176	8971	64471566
Tardive dyskinesia	21.47	15.26	19	18176	9159	64471378
Frustration tolerance decreased	21.35	15.26	16	18179	6109	64474428
Renal impairment	21.03	15.26	6	18189	135011	64345526
Stress	20.82	15.26	50	18145	60484	64420053
Dissociation	20.63	15.26	12	18183	2999	64477538
Renal failure	20.46	15.26	13	18182	181675	64298862
Drug dependence	20.44	15.26	35	18160	33277	64447260
Amnesia	20.09	15.26	43	18152	48226	64432311
Palpitations	20.07	15.26	70	18125	104418	64376119
Drug screen positive	20.04	15.26	15	18180	5714	64474823
Self-injurious ideation	19.96	15.26	12	18183	3185	64477352
Road traffic accident	19.79	15.26	33	18162	30712	64449825
Memory impairment	19.68	15.26	61	18134	85621	64394916
Hypersomnia	19.67	15.26	26	18169	19691	64460846
Malaise	19.63	15.26	184	18011	396063	64084474
Malignant neoplasm progression	19.56	15.26	4	18191	112867	64367670
Change in seizure presentation	19.52	15.26	6	18189	301	64480236
Dyspnoea	19.47	15.26	121	18074	718553	63761984
Energy increased	18.92	15.26	11	18184	2747	64477790
Bradycardia	18.88	15.26	5	18190	118214	64362323
Multiple organ dysfunction syndrome	18.86	15.26	3	18192	101410	64379127
Product dose omission issue	18.68	15.26	106	18089	194641	64285896
Mental impairment	18.59	15.26	23	18172	16320	64464217
Bruxism	18.58	15.26	12	18183	3612	64476925
Drug effective for unapproved indication	18.33	15.26	12	18183	3696	64476841
Contraindicated product administered	18.32	15.26	4	18191	107825	64372712
Impaired work ability	18.25	15.26	22	18173	15197	64465340
Death	17.77	15.26	73	18122	482632	63997905
Dry mouth	17.74	15.26	47	18148	60371	64420166
Septic shock	17.74	15.26	4	18191	105433	64375104
Muscle twitching	17.35	15.26	24	18171	18974	64461563
Somnolence	17.06	15.26	107	18088	203538	64276999
Wernicke-Korsakoff syndrome	17.04	15.26	4	18191	70	64480467
Ankyloglossia congenital	16.70	15.26	3	18192	12	64480525
Intestinal pseudo-obstruction	16.49	15.26	9	18186	1991	64478546
Brain injury	16.41	15.26	17	18178	9948	64470589
Synovitis	16.19	15.26	4	18191	99086	64381451
Anorgasmia	16.12	15.26	7	18188	942	64479595
Illness	16.10	15.26	25	18170	21913	64458624
Vision blurred	16.05	15.26	59	18136	90257	64390280
Paralysis	15.97	15.26	18	18177	11577	64468960
Insulinoma	15.89	15.26	4	18191	95	64480442
Therapeutic response changed	15.87	15.26	7	18188	977	64479560
Hypotension	15.70	15.26	55	18140	380919	64099618
Aggression	15.70	15.26	38	18157	46194	64434343
Vertigo	15.43	15.26	44	18151	58967	64421570

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AX23	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
FDA MoA	N0000000102	Norepinephrine Uptake Inhibitors
FDA MoA	N0000000109	Serotonin Uptake Inhibitors
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D000068760	Serotonin and Noradrenaline Reuptake Inhibitors
FDA EPC	N0000175749	Serotonin and Norepinephrine Reuptake Inhibitor
FDA MoA	N0000182137	Cytochrome P450 2D6 Inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:83399	marine xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000
Generalized anxiety disorder	off-label use	21897009	DOID:14320
Social phobia	off-label use	25501002	DOID:11257
Menopausal flushing	off-label use	198436008
Neuropathic pain	off-label use	247398009
Panic disorder	off-label use	371631005	DOID:594
Ocular hypertension	contraindication	4210003	DOID:9282
Suicidal thoughts	contraindication	6471006
Hypercholesterolemia	contraindication	13644009
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Cerebrovascular disease	contraindication	62914000	DOID:6713
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hyponatremia	contraindication	89627008
Seizure disorder	contraindication	128613002
Bleeding	contraindication	131148009
Impaired renal function disorder	contraindication	197663003
Mania	contraindication	231494001
Hypomania	contraindication	231496004
Interstitial lung disease	contraindication	233703007	DOID:3082
Disease of liver	contraindication	235856003	DOID:409
Hypertriglyceridemia	contraindication	302870006
Serotonin syndrome	contraindication	371089000
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.79	acidic
pKa2	9.33	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 100MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 100MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 25MG BASE	PRISTIQ	PF PRISM CV	N021992	Aug. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 25MG BASE	PRISTIQ	PF PRISM CV	N021992	Aug. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 50MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 50MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	7.33	WOMBAT-PK	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	6.28	WOMBAT-PK	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.22	CHEMBL

External reference:

ID	Source
D07793	KEGG_DRUG
4027338	VUID
N0000176142	NUI
386750-22-7	SECONDARY_CAS_RN
93414-04-1	SECONDARY_CAS_RN
4027338	VANDF
C1880288	UMLSCUI
CHEBI:83527	CHEBI
CHEMBL1118	ChEMBL_ID
CHEMBL1201728	ChEMBL_ID
DB06700	DRUGBANK_ID
7158	IUPHAR_LIGAND_ID
8361	INN_ID
NG99554ANW	UNII
125017	PUBCHEM_CID
683693	RXNORM
132507	MMSL
200628	MMSL
25184	MMSL
339716	MMSL
38906	MMSL
d07113	MMSL
012574	NDDF
012575	NDDF
015249	NDDF
430267008	SNOMEDCT_US
430271006	SNOMEDCT_US
433292007	SNOMEDCT_US
D000069468	MESH_DESCRIPTOR_UI
CHEMBL3989861	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1210	TABLET, EXTENDED RELEASE	25 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1210	TABLET, EXTENDED RELEASE	25 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1211	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1211	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1222	TABLET, EXTENDED RELEASE	100 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1222	TABLET, EXTENDED RELEASE	100 mg	ORAL	NDA	31 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0400	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0401	TABLET, FILM COATED, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0603	TABLET, FILM COATED, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3659	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3659	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3660	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3660	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4060	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4060	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	35208-009	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	35208-010	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
PristiqExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	43063-262	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	31 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-152	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-153	TABLET, EXTENDED RELEASE	100 mg	ORAL	NDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-540	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-541	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-542	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4069	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA AUTHORIZED GENERIC	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4388	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4806	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	50090-5274	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	50090-5293	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-021	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-022	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections